Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azilsartan
Drug ID BADD_D00200
Description Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.[A7354] Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension.[A232863] Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease,[A7354] early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.[L32918] Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure.[A232863]
Indications and Usage Treatment of hypertension (alone or as an adjunct).
Marketing Status Not Available
ATC Code Not Available
DrugBank ID DB08822
KEGG ID D08864
MeSH ID C521273
PubChem ID 135415867
TTD Drug ID D05FGG
NDC Product Code 69037-0032
Synonyms azilsartan | 2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid | TAK-536
Chemical Information
Molecular Formula C25H20N4O5
CAS Registry Number 147403-03-0
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angioedema23.04.01.001; 10.01.05.009--Not Available
Asthenia08.01.01.001--Not Available
Blood creatinine increased13.13.01.004--
Cough22.02.03.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.005--Not Available
Fatigue08.01.01.002--
Gastrointestinal disorder07.11.01.001--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Platelet disorder01.08.03.001--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Connective tissue disorder15.06.01.006--Not Available
Mediastinal disorder22.09.03.001--Not Available
Renal impairment20.01.03.010--Not Available
The 1th Page    1    Total 1 Pages